How much revenue does PharmaEngine make?

PharmaEngine reported 911.42 million TWD in revenue for fiscal year 2025, down 63.9% from 2.52 billion TWD in fiscal year 2024. In Q2 2026 revenue was 258.02 million TWD.

What companies are similar to PharmaEngine?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Gongwin Biopharm Holdings Co., Ltd. (6617.TWO), Foresee Pharmaceuticals Co., Ltd. (6576.TWO), Taho Pharma (6467.TWO), Acepodia, Inc. (6976.TWO).

PharmaEngine, Inc. (4162.TWO) Stock

About PharmaEngine, Inc.

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is also developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hem...

At a glance

PharmaEngine reported revenue of 911.42 million TWD for fiscal year 2025, down 63.9% from fiscal year 2024, and net income of 387.64 million TWD. In Q2 2026 (the quarter ended June 30, 2026) revenue was 258.02 million TWD, up 31.1% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.